Boston BioCom Announces Production of First HSP-Avidin Fusion Proteins for its Jantibody Therapeutics Subsidiary in Collaborative Research Program with Pfenex Inc.

BOSTON--(BUSINESS WIRE)--Boston BioCom LLC today announced the successful completion of a collaborative research agreement between its Jantibody Therapeutics LLC subsidiary and Pfenex Inc., resulting in the rapid production of a HSP-avidin fusion protein for the Jantibodies self-assembling vaccines platform. Jantibody Therapeutics was created by Boston BioCom to commercialize a novel class of immunologically-enhanced monoclonal antibodies (mAbs) that utilize heat shock protein 70 (HSP 70) for initial applications in oncology and infectious diseases, as well as a self-assembling HSP vaccine platform that can be used to enhance the effectiveness of existing mAbs and to readily generate cancer vaccines as well as vaccines for emerging infectious diseases.

Back to news